Ajanta Pharma said the US FDA has issued Form-483 with five observations after inspecting its Paithan manufacturing facility in Maharashtra from April 13–21, 2026. The company stated it will respond within the stipulated timeframe, while noting that Form-483 is issued when inspectors observe potential regulatory violations.

India's metabolic therapy market is transforming post-semaglutide patent expiry, shifting to a competitive, volume-driven model. With significant price drops and increased launches, demand is surging among millions needing obesity management. Broader specialist adoption and a growing prescriber base are fueling this expansion, promising substantial market growth.

… in the highly successful weight-loss drugs called “Ozempic” and “Wegovy” developed … such as Mankind Pharma Ltd., Ajanta Pharma Ltd., Sun Pharmaceutical Industries Ltd. and … nearly 20% of all generic drugs available globally. The most significant impact …

On March 13, Indian stock indices Sensex and Nifty 50 faced continued selling pressure due to rising crude oil prices and global economic concerns. GIFT Nifty today suggests a mildly positive start, with several stocks recommended for buying, including Ajanta Pharma and Power Grid Corporation.

The family office of the founders of Ajanta Pharma in India may inject up to Rs8bn ($88m) into RBA.

Private equity firm Everstone is set to exit Restaurant Brands Asia, the franchisee for Burger King in India and Indonesia. The firm will sell its entire 11.26% stake. The Ajanta Pharma family office is poised to become the new strategic investor. This move could see the family office injecting significant funds and potentially acquiring a majority stake in the company.

Indian speciality pharmaceutical firm Ajanta Pharma is understood to be eyeing a manufacturing operation in Ireland.

Indian drugmaker Biocon has announced the signing of an out-licensing agreement with Ajanta Pharma to market its vertically integrated drug product, semaglutide, used to improve glycemic control in adults with type-2 diabetes.

India’s equity benchmarks closed little changed on Wednesday in a subdued session marked by thin year-end volumes, with losses in information technology stocks weighing on sentiment. The Nifty 50 fell 0.13% to 26,142.1, while the BSE Sensex shed 0.14% to 85,408.7. Fifteen of the 16 major sectors declined. Small-caps rose 0.3%, while mid-caps fell 0.6%. Analysts said thin year-end trading kept volatility in check, with global volumes typically light ahead of the Christmas and New Year holidays. Indian markets will be closed on Thursday for Christmas. Investors are awaiting further cues, including a potential India-U.S. trade deal and October-December earnings, for a directional trade in the market. Motilal Oswal Financial Services said the earnings revision trends in the past four months have beaten its expectations. “The backdrop for earnings has improved vs last year, engineered by a series of stimulative fiscal and monetary measures,” the brokerage firm said. IT stocks fell 0.5% on the day after U.S.